Article Data

  • Views 881
  • Dowloads 133

Reviews

Open Access

Recurrent ovarian cancer with supraclavicular lymph node metastasis: a report of two cases and literature review

  • Pei-Liang Zhao1
  • An-Yang Liu1
  • Yi-Zhou Bai1
  • Qin-Ping Liao2
  • Bin Luo1,*,

1Department of General Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, 102218 Beijing, China

2Department of Gynaecology and Obstetrics, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, 102218 Beijing, China

DOI: 10.31083/j.ejgo.2021.02.2094 Vol.42,Issue 2,April 2021 pp.207-212

Submitted: 22 March 2020 Accepted: 17 June 2020

Published: 15 April 2021

*Corresponding Author(s): Bin Luo E-mail: lba01097@btch.edu.cn

Abstract

Recurrent ovarian cancer is commonly associated with lymphatic metastasis, however, supraclavicular lymph node is a rare site for metastasis. Few studies have investigated whether local debulking surgery would benefit patients with supraclavicular lymph node metastasis. We report two such cases, review the literature and discuss the potential for local debulking surgical treatment for this rare scenario. Both cases were diagnosed with recurrent ovarian cancer, with the first having left supraclavicular lymph node metastasis, while the second had right supraclavicular lymph node metastasis. Cervical lymphadenectomy was performed to relieve local symptoms in both cases followed by chemotherapy. The first case died of hepatic hilar metastasis 6 months after the surgery while the second case has to date (January 2020) survived without any recurrence 12 months postoperatively. A comprehensive search in the PubMed, Embase, and Cochrane databases was performed. According to the limited study and our cases, we conclude the lymphanectomy appears to provide potential benefit to patients with oligometastasis like right supraclavicular lymph node metastasis.

Keywords

Ovarian cancer; Surgery; Supraclavicular lymph node

Cite and Share

Pei-Liang Zhao,An-Yang Liu,Yi-Zhou Bai,Qin-Ping Liao,Bin Luo. Recurrent ovarian cancer with supraclavicular lymph node metastasis: a report of two cases and literature review. European Journal of Gynaecological Oncology. 2021. 42(2);207-212.

References

[1] Cebesoy FB, Balatt O, Aydin A. Virchow’s node as a first manifestation of ovarian serous carcinoma: case report. European Journal of Gynaecological Oncology. 2008; 29: 182–183.

[2] Fanti S. Supra-clavicular lymph node metastatic spread in patients with ovarian cancer disclosed at 18F-FDG-PET/CT: an unusual finding. Cancer Imaging. 2006; 6: 20–23.

[3] Hong L, Qiu H, Mei Z, Zhang H, Liu S, Cao H. Ovarian cancer initially presenting with supra-clavicular lymph node metastasis: a case report. Oncology Letters. 2019; 16: 505–510.

[4] Mayadevi S, Nagarajan S, Van Der Voet JCM, Nevin J, Cruick- shank DJ. Metastatic adenocarcinoma of right supraclavicular fossa-delayed presentation of ovarian primary. Journal of Obstet- rics and Gynaecology. 2005; 25: 528–529.

[5] Rahman M, Nakayama K, Rahman MT, Katagiri H, Ishibashi T, Miyazaki K. Enlarged Virchow’s node as an initial complaint of serous ovarian adenocarcinoma. European Journal of Gynaecological Oncology. 2012; 33: 546–548.

[6] Tanaka T, Ohmichi M. Recurrent ovarian cancer presenting in the right supraclavicular lymph node with isolated metastasis: a case report. Journal of Medical Case Reports. 2012; 6: 176.

[7] National Comprehensive Cancer Network. The NCCN ovarian cancer clinical practice guidelines in oncology (version 1.2020). NCCN, Fort Washington. 2020.

[8] Gadducci A, Cosio S, Zola P, Sostegni B, Ferrero AM, Teti G, et al. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study. Gynecologic Oncology. 2010; 116: 358–363.

[9] Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA: A Cancer Journal for Clinicians. 2019; 68: 280–304.

[10] Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. The Lancet. 2019; 393: 1240–1253.

[11] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians. 2020; 70: 7–30.

[12] Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine. 2011; 365: 2473–2483.

[13] Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine. 2011; 365: 2484–2496.

[14] Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebocontrolled phase iii trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. Journal of Clinical Oncology. 2012; 30: 2039–2045.

[15] Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecologic Oncology. 2015; 139: 10–16.

[16] Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. 2017; 18: 779–791.

[17] Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA openlabel randomized phase III trial. Journal of Clinical Oncology. 2014; 32: 1302–1308.

[18] Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebocontrolled study. The Lancet Oncology. 2012; 13: 154–162.

[19] Tew WP, Colombo N, Ray-Coquard I, del Campo JM, Oza A, Pereira D, et al. Intravenous aflibercept in patients with platinumresistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer. 2014; 120: 335–343.

[20] Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae D, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. The Lancet. Oncology. 2014; 15: 799–808.

[21] Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae D, et al. Final results of a phase 3 study of trebananib plus weekly pacli- taxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free survival-2. Gynecologic Oncology. 2016; 143: 27–34.

[22] Miao M, Deng G, Luo S, Zhou J, Chen L, Yang J, et al. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer. Gynecologic Oncology. 2018; 148: 286–290.

[23] Balasubramaniam S, Beaver JA, Horton S, Fernandes LL, Tang S, Horne HN, et al. FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer. Clinical Cancer Research. 2017; 23: 7165–7170.

[24] Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. Journal of Clinical Oncology. 2010; 28: 2512–2519.

[25] Scott LJ. Niraparib: first global approval. Drugs. 2017; 77: 1029–1034.

[26] Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody Avelumab (MSB0010718C) on human tumor cells. Cancer Immunology Research. 2015; 3: 1148–1157.

[27] Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. Journal of Clinical Oncology. 2015; 33: 4015–4022.

[28] Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. New England Journal of Medicine. 2019; 381: 1929–1939.

[29] Hellman S, Weichselbaum RR. Oligometastases. Journal of Clinical Oncology. 1995; 13: 8–10.

[30] Giuliani ME, Robinson CG, Salama JK, Daly ME. Oligoreview of non-small cell lung cancer oligometastases. International Journal of Radiation Oncology, Biology, Physics. 2020; 106: 455–459.

[31] Massaut E, Bohlok A, Lucidi V, Hendlisz A, Klastersky J, Donckier V. The concept of oligometastases in colorectal cancer. Current Opinion in Oncology. 2018; 30: 262–268.

[32] Battaglia A, De Meerleer G, Tosco L, Moris L, Van den Broeck T, Devos G, et al. Novel insights into the management of oligometastatic prostate cancer: a comprehensive review. European Urology Oncology. 2019; 2: 174–188.

[33] Kwapisz D. Oligometastatic breast cancer. Breast Cancer. 2019; 26: 138–146.

[34] Mizutani M, Nawata S, Hirai I, Murakami G, Kimura W. Anatomy and histology of Virchow’s node. Anatomical Science International. 2005; 80: 193–198.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top